Current stock page

Stock Analysis

Zenas BioPharma, Inc. (ZBIO) Stock Analysis

Zenas BioPharma, Inc. (ZBIO) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

ZBIO Stock Analysis Summary

Zenas BioPharma, Inc. (ZBIO) currently has an AIQ Score of 47/100, indicating a bearish setup. Momentum is the strongest factor at 78/100. Quality is the weakest current factor at 25/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

ZBIO at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$28.01
AIQ Score47/100
Overall ViewBearish
Technical Analysis ConsensusNeutral
Market Cap$1.85B
P/E Ratio (TTM)-2.79
Forward P/E—
EPS (Q3 FY2026)-$1.65
Revenue (Q3 FY2026)$10M
Dividend Yield (TTM)0.00%
Beta0.75
Volume304.83K
52-week range$13.50-$44.60
RSI 1450.08
50-Day SMA$28.58
200-Day SMA$25.34
Analyst Price Target$55.00
Next EarningsMar 15, 2027
As of Nov 13, 2026 · Market close

ZBIOZenas BioPharma, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

BearishEdge 4/10
$28.01+$0.37 (+1.34%)

Latest quote

  • Momentum
    78
  • Value
    33
  • Quality
    25
  • Risk resilience
    39
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

ZBIO Stock Analysis Summary

Zenas BioPharma, Inc. (ZBIO) currently has an AIQ Score of 47/100, indicating a bearish setup. Momentum is the strongest factor at 78/100. Quality is the weakest current factor at 25/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, ZBIO has AIQ Score of 47/100 with Momentum base of 78/100 and fading Quality at 25/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (78/100) leads while Quality (25/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 1.34% stock move · ZBIO classified in Biotechnology.

Current Evidence

BearishZBIO is in a bearish AIQ regime; Momentum is the strongest visible factor at 78/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is ZBIO Bullish or Bearish Right Now?

ZBIO currently has a bearish overall setup. Momentum is the strongest factor at 78/100, while Quality is weakest at 25/100. The current evidence suggests a bearish setup.

Bull Case
  • - Momentum is constructive at 78/100.
  • - Analyst target implies +96.36% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (18 vs 13).
Bear Case
  • - Value is the current constraint at 33/100.
  • - Risk Resilience is weak at 39/100.

Current Consensus

ZBIO's Technical Analysis Consensus is currently Neutral, with 18 buy, 15 neutral, and 13 sell votes. ZBIO's 14-day RSI is 50.08, which places the stock in a neutral momentum range. ZBIO's beta is 0.75, indicating lower market sensitivity than the broad market.

Signal Confidence
Moderate agreement

What Changed in ZBIO?

The largest recent change in ZBIO is Momentum moving up by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+1.0
Momentum
+2.0
Quality
+1.0
Risk
+0.0

What Would Change the ZBIO Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

ZBIO Decision Framework

Public evidence layers, setup checks, and risk context for Zenas BioPharma, Inc..

Zenas BioPharma, Inc. (ZBIO) Stock Analysis

Zenas BioPharma, Inc. has an AIQ Score of 47/100 in a Bearish regime. Momentum is strongest at 78/100. Beta is 0.75, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextZBIO is in a Bearish AIQ regime with score 47/100.
Signal ConflictThe primary conflict is that momentum leads at 78/100 while quality lags at 25/100.
Factor EvidenceMomentum 78/100 · Value 33/100 · Quality 25/100 · Risk 39/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 78/100.

TimingPass

Momentum is 78/100 and RSI (14) is 50.1.

Regime fitFail

ZBIO is in a Bearish regime at 47/100.

Risk controlFail

Risk factor is 39/100 with beta 0.75 and annual volatility 95.33%.

ConflictWait

Current conflict: momentum leads at 78/100 while quality lags at 25/100.

AIQ Score
47/100
Price
$28.01
Beta
0.75
RSI (14)
50.1

ZBIO Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

ZBIO Fundamentals

ZBIO valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$10M
Net income
-$108.92M
Free cash flow
-$57.99M
View full ZBIO fundamental analysis

ZBIO Technical Analysis

ZBIO technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Neutral
RSI 14
50.08
Price vs SMA-50
-2.00%
View full ZBIO technical analysis

ZBIO Stock Catalysts

Track ZBIO earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 15, 2027
Analyst target
$55.00
News items
0
View ZBIO earnings and stock catalysts

ZBIO Dividend Analysis

ZBIO dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View ZBIO dividend history and analysis

ZBIO Financial Data

ZBIO revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$10M
EPS
-$1.65
Periods
8
View ZBIO financials

ZBIO Risk Analysis

ZBIO volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.75
Risk score
39/100
1Y volatility
95.33%
View ZBIO risk analysis

ZBIO Stock News

ZBIO stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read ZBIO stock news

ZBIO vs Biotechnology Peers

Current peer cohort: ZBIO · ZYME · ABCL · ABSI · ABUS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
ZBIO
Current stock
47/10033/10078/10039/1000.2695.33%Current
ZYME
Zymeworks Inc.
68/10066/10078/10061/1000.8454.03%ZBIO vs ZYME
ABCL
AbCellera Biologics Inc.
64/10047/10089/10034/1001.7385.28%ZBIO vs ABCL
ABSI
Absci Corporation
53/100—85/10030/1001.58104.15%ZBIO vs ABSI
ABUS
Arbutus Biopharma Corp
70/10092/10051/10062/100-0.0945.89%ZBIO vs ABUS
Pairwise Compare links: ZYME · ABCL · ABSI · ABUSZBIO vs ZYMEZBIO vs ABCLZBIO vs ABSIZBIO vs ABUSCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a ZBIO stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for ZBIO: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-2.79
As of Nov 13, 2026
Revenue growth
—
Gross margin
-656.60%
Current debt / equity
1.42
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$10M
Quarter net income
-$108.92M
Quarter free cash flow
-$57.99M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Mixed
RSI 14
50.08
MACD
0.02

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
39/100
Beta
0.75
Annual volatility
95.33%
Max drawdown
-64.79%

ZBIO Stock FAQ

What is ZBIO stock price today?

Zenas BioPharma, Inc.'s current stock price is $28.01. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is ZBIO bullish or bearish right now?

ZBIO's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is ZBIO's market cap?

ZBIO's market cap is $1.85B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is ZBIO's current P/E ratio?

ZBIO's current P/E ratio is -2.79 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is ZBIO's RSI?

ZBIO's 14-day RSI is 50.08 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is ZBIO above its 50-day and 200-day moving averages?

ZBIO is -2.00% from its 50-day SMA and 10.53% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is ZBIO's next earnings date?

ZBIO's next earnings date is currently listed as Mar 15, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does ZBIO pay a dividend?

ZBIO's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.